Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Review

Immunotherapeutic nanoparticles: From autoimmune disease control to the development of vaccines

Romina Mitarotonda

Exequiel Giorgi

Tatiane Eufrasio-da-Silva

Alireza Dolatshahi-Pirouz

Yogendra Kumar Mishra

Ali Khademhosseini

Martin F. Desimone

Mauricio De Marzi

Gorka Orive

Laboratorio de Inmunología, Instituto de Ecología y Desarrollo Sustentable (INDES) CONICET-UNLu, Departamento de Ciencias Básicas, Universidad Nacional de Luján, Ruta 5 y Avenida Constitución (6700) Luján, Buenos Aires, Argentina

Department of Health Technology, Technical University of Denmark (DTU), 2800 Kgs. Lyngby, Denmark

Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Department of Dentistry - Regenerative Biomaterials, Philips van Leydenlaan 25, 6525EX Nijmegen, the Netherlands

Mads Clausen Institute, NanoSYD, University of Southern Denmark, 6400 Sønderborg, Denmark

Department of Bioengineering, Center for Minimally Invasive Therapeutics (C-MIT), California NanoSystems Institute, University of California, Los Angeles, CA 90095, USA

Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, CA 90095, USA

Terasaki Institute for Biomedical Innovation, Los Angeles, CA 90064, USA

Jonsson Comprehensive Cancer Center, Department of Radiology, University of California, Los Angeles, CA 90095, USA

Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Instituto de la Química y Metabolismo del Fármaco (IQUIMEFA), Facultad de Farmacia y Bioquímica, Buenos Aires, Argentina

NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country UPV/EHU, Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain

Biomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain

Bioreatha, NanoBioCel Research Group, Vitoria-Gasteiz, Spain

University Institute for Regenerative Medicine and Oral Implantology - UIRMI (UPV/EHU-Fundación Eduardo Anitua), Vitoria, Spain

Singapore Eye Research Institute, The Academia, 20 College Road, Discovery Tower, Singapore

ARTICLE INFO

Keywords:
Immunomodulation therapy
Nanoparticles
Allergy
Autoimmune disease
Immune stimulation
Immunosuppressants

ABSTRACT

The development of nanoparticles (NPs) with potential therapeutic uses represents an area of vast interest in the scientific community during the last years. Recently, the pandemic caused by COVID-19 motivated a race for vaccines creation to overcome the crisis generated. This is a good demonstration that nanotechnology will most likely be the basis of future immunotherapy. Moreover, the number of publications based on nanosystems has significantly increased in recent years and it is expected that most of these developments can go on to experimentation in clinical stages soon. The therapeutic use of NPs to combat different diseases such as cancer, allergies or autoimmune diseases will depend on their characteristics, their targets, and the transported molecules. This review presents an in-depth analysis of recent advances that have been developed in order to obtain novel nanoparticulate based tools for the treatment of allergies, autoimmune diseases and for their use in vaccines. Moreover, it is highlighted that by providing targeted delivery an increase in the potential of vaccines to induce an immune response is expected in the future. Definitively, the here gathered analysis is a good demonstration that nanotechnology will be the basis of future immunotherapy.

* Corresponding authors.
** Corresponding authors at: NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country UPV/EHU, Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain.
E-mail addresses: desimone@ffyb.uba.ar (M.F. Desimone), mdemarzi@unlu.edu.ar (M. De Marzi), gorka.orive@ehu.eus (G. Orive).

https://doi.org/10.1016/j.bioadv.2022.212726
Received 9 August 2021; Received in revised form 9 February 2022; Accepted 18 February 2022
Available online 22 April 2022
2772-9508/© 2022 Elsevier B.V. All rights reserved.
1. Introduction

Immunomodulating agents are substances that have the ability to increase or decrease the immune response. From a therapeutic point of view, this modulation capacity has broad potential as adjuvant therapy in neoplastic, allergic and immunodeficient diseases. The immune system is formed by a set of cells, molecules and tissues organized to defend the body from foreign agents and maintain homeostasis. This is a complex control system used to fight pathogens as well as to maintain a dynamic equilibrium among proimmune/inflammatory processes, regulatory/suppressive functions, and levels of homeostatic activity. The immune response involves the coordination of both innate and adaptive immunity [1,2].

The first line of defense is the innate immunity, often followed by the adaptive immune response. Innate immunity involves physical, chemical and cellular responses against pathogens. Innate immune cells activation (macrophages, neutrophils, mast cells, eosinophils, basophiles, dendritic cells, natural killer cells, among others) is responsible for the secretion of specific cytokines at the reaction site, producing local inflammation. The adaptive immune response frequently follows this initial inflammation. It involves the activation of T and B lymphocytes, which are antigen-specific cells that target pathogens and instigators of the immune system. Both immune responses are interconnected and highly dependent on which pathway of the immune system is activated [3].

At the forefront of recent developments in the treatment of systemic...
diseases, such as inflammatory disorders, is the innovation in agents which can modulate the immune system. In this sense, nanomedicine has emerged as a successful strategy to produce engineered nanomaterials that can target specific organs or tissues [4–7] and deliver therapeutic agents [8,9] while avoiding undesirable immunosuppressive or immunostimulatory effects [10–13]. Indeed, various nanomaterials are under different stages of clinical trials or have been approved by the United States Food and Drug Administration (FDA) [14]. Fig. 1 shows a schematic representation of different smart nano-systems. The impact of these nanoparticles (NPs) on the immune response for use with therapeutic purposes (i.e.: inflammatory, autoimmune, allergic, cancer diseases) will depend on their nature (i.e.: composition, size, charges, stiffness, shape, roughness, etc.) as well as their labeling and targeting (i.e.: antibodies) and the cargo it carries (i.e.: molecules, antigens, cytokines, drugs, immunoregulatory agents, etc.) (Fig. 1). For example, cell uptake and intracellular distribution or circulation time and elimination rate are mediated by particle shape [15]. Moreover, the analysis is more complex considering diverse species, models and associated methodologies employed to assess the immune responses to NPs [16].

Definitively, the characteristics of NPs can be exploited to modulate the immune system [17]. For example, the purpose of modulation will be to increase the intensity of the immune response that is diminished by some causes (i.e.: immunosuppression, stress, chronic infections), while in other cases, it will be reduced when it is out of regulation or control (i.e.: autoimmune diseases, allergies, transplants, hypersensitivity). NPs can be applied from two different approaches:

(i) Using NPs as adjuvants to modify the specific response of immune cells subsets. In particular, the adjuvant activity of NPs depends on their physiochemical properties and their capacity to be internalized in different cells, which can modify their responses. Moreover, the preferential access to specific immune cell populations would be achieved with the development of engineered nanosized carriers grafted with targeting moieties.

(ii) Designing NPs in order to reach a subset of immune cells. This would be the basis for the development of immunotherapy that involves the stimulation of the immune response through the
administration of immunomodulatory molecules. For these purposes, the characteristics of the nanocarriers (i.e.: particle size, surface charge or shape) can be modified to facilitate their interaction with immune cells; however, cell-specific activation and selective recognition can only be achieved through the use of active targeting ligands.

Based on the characteristics of the immune system and the NPs of different materials, immunomodulatory therapies using nanomaterials have been investigated and designed. For example, Scheibholzer et al. reviewed research in which by covalently linking allergens and polysaccharides to NPs, a versatile hypoallergenic tool that specifically target antigen-presenting cells can be obtained [18]. On the other hand, publications such as Jurj et al. and Jia et al. summarize the research and developments of nanoscale immunotherapy and drug delivery for cancer by activating the immune system for clinical purpose [19,20].

Different NPs were developed to induce immune response against cancer cells, override cancer-mediated immunosuppression, or generate long-term disease control with memory immune cells [21]. Other investigations describe the use of NPs and microparticles as delivery systems for immunomodulatory agents or the immunomodulatory effects of NPs themselves (22–26). In this sense, Fig. 2 presents a scheme of the NPs characteristics that can be exploited to modulate the immune system response. In short, NPs could be used as immunomodulatory tools with immunosuppressive or immunogenic properties. In the first case, immunosuppressive NPs could be used to stop an undesirable immune response (autoimmune or allergic diseases), while immunogenic NPs could transport cytokines and molecules that enhance the immune response (useful for immunosuppressed patients’ treatment). In addition, immunotherapeutic NPs for cancer and adjuvant NPs to improve vaccines are continuously being developed [27–32]. For example, the innate immune response through macrophages, natural killer cells (NKs), neutrophils and dendritic cells (DCs) has the ability to kill tumor cells. In this sense, tumor-associated antigens stimulate the maturation of DCs which in turn migrate to lymph nodes. Once in lymph nodes, promotes the activation of T cells (adaptive immune system). Subsequently, activated T cells migrate and recognize tumor cells antigens. Finally, tumor cells are killed by cytotoxic T cells (Fig. 3). Nanosystems would contribute to radiotherapy, chemotherapy and/or immunotherapy developments for cancer treatments [33–39] (Fig. 3).

2. Therapeutic strategies with nano and microparticles for autoimmune and allergies treatment

2.1. The fundamental role of the immune system

The immune response plays a fundamental role in the maintenance of homeostasis, since it is an important system for the protection of the body against foreign substances and signs of danger, but an abnormal immune response, which could include both, a state of immunosuppression and immune stimulation, will inevitably lead to the disease. Recent studies reveal that both, the inflammatory processes (immune stimulation) as well as the presence of immunological tolerance (absence of reaction against own antigens or some foreign antigens that are innocuous) are influenced by the way in which antigens are presented [40,41]. A process of immune stimulation can give rise to a strong adverse response, as in the case of autoimmune diseases. These are a group of pathologies that occur when the tissues of the body are attacked by their own immune system. On the other hand, allergic diseases are a series of conditions caused by a hypersensitivity reaction of the immune system to substances in the environment that are typically harmless. Immunosuppressants are among the most used drugs for autoimmune diseases and allergies treatment. These drugs reduce or inhibit the self-reaction of the immune response but have a number of adverse effects.

2.2. Engineered nanoparticles as therapeutic tools for autoimmune and allergies diseases treatment

It has been described that NPs, once inside the body, depending on the route by which they do it, will find phagocytic cells, such as macrophages and DCs or molecules, such as components of complement. When administered in living systems, NPs act as foreign materials and can suppress and/or stimulate the immune system [42]. These effects are determined by their chemistry nature [43] and in many cases, may be undesirable. However, NPs could decrease or increase the immune response, thus their immunomodulation properties could be useful for several diseases prevention or treatment [44–46]. In this way, the understanding of NPs and immune system interaction became fundamental for NPs application in clinical treatment in a safe way.

It would be possible to think that NPs that causes immunosuppressive effects could be used as anti-inflammatory therapeutic agents or to counteract the effects of autoimmune or allergic diseases. Unlike, NPs that stimulate the immune system could be employed as vaccine adjuvants or in cancer therapy [47] (Fig. 3). In the particular case of the treatment of autoimmune diseases it would be ideal that NPs generate phenotypes of anti-inflammatory M2 macrophages. The generation of this profile depends not only on the size of the NPs (their small size allows them to cross cell membranes and interact with biological molecules), but also on the material with which NPs have been generated, since some have been described as suppressors of the immune response [48]. Thus, it is possible to denominate as tolerogenic NPs the tool that researchers are trying to obtain for autoimmune disease treatment or allergies suppression.

Tolerance can be defined as the balance between molecules and cells of the immune system that avoid the response against self-antigens or harmless foreign antigens. When this process became unbalanced autoimmune pathologies and allergies appear. NPs are interesting candidates as potential immunotherapeutics. As mentioned before, NPs can subvert, enhance or suppress the immune system [42]. This effect can be achieved by particles to deliver genes, proteins or drugs and recent results have yielded models of NPs based therapies for controlling severe inflammation in autoimmune disease without impairing immunity against infections and tumors [49–53]. As can be seen in Fig. 3, the cargo carried by the NPs together with the targeting that can be given to them by attaching antibodies and/or ligands to their surface could transform them into useful tools for the treatment of autoimmune diseases such as multiple sclerosis, lupus, psoriasis, diabetes, etc. Regulatory T cells (Tregs) are responsible for controlling or suppressing other cells of the immune system and the response against both self and foreign antigens, helping to prevent autoimmune diseases. For example, damaged beta cells in the pancreas release specific proteins that would be recognized as antigens. This would lead to phagocytosis and maturation of DCs. In the pancreatic lymph node mature DCs interacts with T cell causing the activation of the adaptive immune response. Furthermore, activated B cell produces autoantibodies which recognize autoantigens. In conclusion, an inflammatory response is generated which further attacks pancreatic islets (Fig. 3). In this sense, immunosuppressive NPs with therapeutic molecules would greatly contribute to suppress this type of autoimmune disease (Fig. 3). Indeed, autoimmune diseases are associated with a decreased function of Tregs, so one of the objectives of therapy will be focused in restore Tregs activity [54–56].

2.3. Immunosuppressive nanoparticles

Several works described NPs of different materials with immunosuppression activities by itself [57,58]. The common limitations of current immunosuppressive and biological therapies can be overcome with nanotechnology based strategies [58]. In this section, key examples of the effect of NPs with different composition are analyzed. Moreover, Table 1 presents a summary of NPs assayed for autoimmune and allergies diseases treatment.
Fig. 3. Representation of anti-inflammatory nanosystems for the treatment of different autoimmune diseases with special focus, as pathophysiological model, in type 1 diabetes progression (upper part of the figure) or as immunotherapeutics against cancer where it can be seen the different stages of innate and adaptive immunity where nanosystems can intervene (lower part of the figure).
2.3.1. Carbon based particles

2.3.1.1. Carbon nanotubes (CNTs). CNTs can generate immunosuppressive effects depending on how they are administered. The inhalation of CNTs induced systemic immunosuppression in mice with increase gene expression of IL-10 in spleen (an anti-inflammatory cytokine), reduced T cell proliferation and decreased NK cell function in C57BL/6 adult mice [59]. On the contrary, the effect of CNTs in the same adult mice but with intravenously administration resulted in a Th2 immune responses (T helper type 2 -Th2- cells are CD4+ effector cells, required for humoral immunity and with an important role in coordinating the immune response to large extracellular pathogens and in allergies) that could promote allergic reactions with neutrophil influx, increase IL-5, IL-4 and a critical role of IL-33 [59,60]. While other authors described that certain forms of CNTs induce inflammatory processes and fibrosis in the lungs [61]. However, other studies confirmed that aspiration of CNTs in a mice model have direct effects on DCs, modulating systemic immunity and suppressing the responsiveness of T cells [62]. According to this, Moraes et al. described that the stimulation of antigen presenting cells (APCs) with CNTs increase IL-27 levels and inhibit the development of the Th17 cells (a type of effectors T cells and neutrophils influx. Increase IL-5, IL-4 and promote a critical role of IL-33 [59,60]. These observations were based primarily in the free radical scavenger capacity of fullerenes since free radicals are important as messengers in the pathogenesis of arthritis.

2.3.1.2. Fullerenes and graphene. Fullerene, an allotrope of carbon, was described to have anti-inflammatory effects and interfere with the innate immune system in a fish model causing inhibition of oxidative burst and suppression of NETs release (DNA mesh that encloses histones and antimicrobial proteins, released by neutrophils into the extracellular space) as well as degranulation of neutrophils [64]. In the same way, type I hypersensitivity was suppressed by C60 fullerene. This carbon NPs decrease the release of histamine by human mast cells and the level of reactive oxygen species (ROS), that could be a potential way to control asthma, inflammatory arthritis and multiple sclerosis [44]. Other authors observed that fullerene suppressed induction of the proinflammatory cytokine TNF-α in human cells (fibroblast, lymphocytes and macrophages), and reduced synovitis in a rat arthritis model [65]. These observations were based primarily in the free radical scavenger capacity of fullerenes since free radicals are important as messengers in the pathogenesis of arthritis.

Alternatively, graphene oxides have important therapeutic applications such as their potential use to reduce inflammation as described in an autoimmune encephalomyelitis and sepsis models [66,67]. However, in some cases, nanotoxicity hinders its application. Indeed, acute graphene oxide exposure induces innate immune gene expression but the innate immune response is considerably less pronounced after acute amino-functionalized graphene oxide exposure [68]. On the other hand graphene oxide NPs with surface modifications were described as an useful potential tool to improve its biocompatibility with the aim to employ them as both carriers and adjuvants. Functionalized graphene oxide was shown to activate both cellular and humoral immunity, that is why it was postulated as a true vaccine component carrier and adjuvant [69].
2.3.1.3. Polymeric nanoparticles. Polymeric NPs are polymers within the size range of 1 to 1000 nm of different nature. These can be loaded with active compounds trapped inside or adsorbed on their surface. Polymeric NPs have shown great potential for targeted drug delivery for the treatment of various diseases.

2.3.1.3.1. Polystyrene nanoparticles. Some polymeric NPs have been shown to inhibit inflammatory processes in vivo, as observed in the lungs of mice previously exposed to an allergen and after intratracheal administration of polystyrene NPs. These NPs inhibited the proliferation of lung DCs and lymph node drainage [70]. Alternatively, poly-electrolyte nanocapsules were efficiently applied to transfer different RNAs to various cell lines including primary T cells [71]. Moreover, by using carboxyl- and amino-functionalized polystyrene NPs, Fuchs et al., demonstrated that the surface modification is a valuable tool for reprogramming the M1/M2 polarization macrophage subsets [72]. While polystyrene 50-nm NPs coated with glycine, a neutral amino acid, are not inflammatory and are taken up preferentially by DCs in the periphery [70]. Although, it has been found that there are no significant alterations in oxidative stress neither pathological change in liver, lung or cortex tissues when polystyrene NPs were administrated orally for 30 days in mice [73].

2.3.1.3.2. DNA nanoparticles. Other polymeric NPs under development that represent a promising approach to treat a wide variety of clinical diseases are DNA nanoparticles (DNPs). These NPs are widely used as vehicles for gene knock down, gene transduction or gene transfer. On the other hand, it was described that immunity and autoimmunity can be suppressed after systemic administration of DNPs in mice models. DNPs stimulated the activity of a subset of splenic DCs specialized to activate Foxp3-lineage regulatory CD4 T cells (Tregs) and suppress effector T cell responses. One way to avoid the release of the stimulating IFNγ in response to DNPs is the removal of CpG motifs from cargo DNA. Different DNPs delivery routes are frequently employed to provoke immunogenic responses however systemic administration was the most important to incite regulatory responses. DNP treatments attenuated antigen-induced arthritis and EAE in mice indicating that regulatory responses to DNPs were critically dependent on DCs activity. DNPs reduced pro-inflammatory cytokine production and antigen-specific T-cell responses in spleen and attenuated T cell infiltration into central nervous system (CNS) tissues [74-78]. On the contrary, DNA microparticles made of cytosine–phosphate–guanosine oligodeoxynucleotides arranged into 3D nanostructures were developed to improve the serum stability and immunostimulatory effect. Interestingly, these DNA capsules can serve as both adjuvants to stimulate an immune reaction and vehicles to encapsulate vaccine peptides/genes to achieve synergistic immune effects [79]. Definitively, in the last years, there are increase evidence demonstrating that nucleic acid NPs can be used to modulate the immune response [80].

2.3.2. Non-carbon-based nanoparticles

2.3.2.1. Gold nanoparticles. It was reported that other NPs with anti-inflammatory properties are citrate coated Gold NPs that inhibited the cellular responses induced by IL-1β in a size dependent manner, both in vitro and in vivo [81]. IL-1β is an important cytokine involved in inflammatory disorders such as rheumatoid arthritis and psoriasis. Beside this, Leonavičienė et al. demonstrated that intra-articular administration of gold NPs reduced inflammation, joint swelling, and the development of polyarthritis [82]. It is important to note that gold compounds have been used from decades to treat rheumatic diseases [82]. A negative consequence of this behavior was described by Swartzwelder et al. (2020). They observed a decrease of BCG-stimulated monocyte response in presence of gold NPs. Indeed, a reduction of the production of TNF-α and IL-6 and in the maintenance of IL-1Ra levels was observed. However, such effect could be important in a context of excessive immune reactions against this or other antigens [83].

2.3.2.2. Cerium oxide nanoparticles. Cerium oxide NPs (nanoceria) have the ability to act as free radical scavengers. Nitric Oxide is an important inflammation mediator. Some studies indicated that nanoceria affect inducible nitric oxide synthase (iNOS) expression and provoke an important anti-inflammatory effect in murine macrophages. For this reason, nanoceria were postulated as potential NPs in chronic inflammation diseases therapy. These NPs also induced the secretion of IL-10 by APCs and Th-2 profile [84,85]. Furthermore, Eitan et al. demonstrated that combination of lenalidomide and nanoceria reduce demyelination and neurological symptoms in EAE mice model by suppressing oxidative stress and inflammation [86]. In the same way, it was demonstrated that nanoceria presents an antiinflammatory effect by down regulation of inflammatory proteins (NF-kB, COX-2 and GSK3) and inhibiting Th-cell mediated IL-17/IL-23 [87].

2.3.2.3. Quantum dots (QDs). It was reported that QDs can produce damage in nuclei, mitochondria, and plasma membrane. Moreover, QDs induce the generation of ROS leading to cell death. In addition, it was observed that sub toxic levels of QDs diminish the levels of TNF-α, IL-8 and nitric oxide in colon epithelial cells and macrophages [88,89]. In this sense, it was demonstrated that graphene QDs, intraperitoneally injected, diminish intestinal inflammation by inhibiting Th1/Th17 polarization in a chronic and acute colitis model as well as switch macrophages polarization to M2 type and increase the presence of Tregs in intestinal tissue [90]. QDs did not generate immune responses in vitro and in vivo although the proliferation of CD4 lymphocytes (T helper cells) and macrophages was affected [91]. Interestingly, the size of the QDs aggregates is of paramount importance in their resulting effect. Indeed, the phagocytes of large aggregates of CdS/CdTe QDs (25–100 nm) is lower than smaller QDs (~25 nm) on fish and bivalves [92]. However, the study of adverse effects of QDs is still under study, such as their effect over liver, kidney, lung, spleen and brain [93].

2.3.2.4. Titanium oxide (TiO2) nanoparticles. TiO2 nanotubes, NPs or fine particles have been described to diminish splenocytes proliferation (~20–35%) in concentrations of 50 μg/ml for NPs and nanotubes or 100 μg/ml for fine particles. These authors also found lower levels of IL-2 and INF-γ in a mix lymphocyte reaction assay, probably by blocking Th-1 cell (T cells that lead to an increased cell-mediated response, typically directed against intracellular bacteria and protozoa) response in vitro [94]. The importance of this finding resides in the fact that low levels of IL-2 maintain Tregs cells activity, preventing autoimmune diseases. Likewise, the inhibition of INF-γ, which is involved in inflammatory response, prevents it from promoting the cytotoxic CD8 T cells involved in the immune cellular response of several autoimmune diseases. On the other hand, in this work slightly elevated levels of IL-4 were found. This molecule, a Th-2 cytokine, induces the production of IgE and mast cell activation, both implicated in allergies diseases. Other work of the same authors, described that TiO2 NPs ameliorate EAE and collagen induced arthritis [94]. On the other hand, it was described that oral consumption of TiO2 NPs increase cytokines levels and the presence of pro-inflammatory immune cells in the colonic mucosa, indicating an inflammatory state [95,96].

2.3.2.5. Silica nanoparticles (SiNPs). The physicochemical properties and biological effects of SiNPs are remarkable [97,98]. Indeed, the development of SiNPs for various purposes has been successfully reported [99–101]. Moreover, a variety of biomedical applications of SiNPs have entered clinical trials [102]. Among them, it is highlighted their use for the administration of bioengineered active agents and drugs, the targeting ability due to molecules on its surface, stimuli responsive behavior (pH, magnetic field, light, temperature, etc.) and their applications for obtaining biomages (Fig. 4). It was observed that the effects of these NPs depend on their concentration, size and charge [103–105]. Indeed, the existence of a size-dependent effect of silica particles on cell
palliation was observed. When THP-1 cultures were exposed to SiO particles, only those of ≥200 nm diminish cell proliferation [106]. In addition, most of the silica particles evaluated, increased the production of nitrites, IL-8 and IL-12. Moreover, the levels of cytokine secretion increase during the times evaluated. However, 10 nm SiOH NPs did not induce the production of nitrites and IL-12 during all times assayed. Similarly, SiO particles induce cell activation, evidenced by an increased expression of CD86, CD80, CD40 and CD14 molecules on the THP-1 cell membrane but all SiO particles except 10 nm ones, which decreases CD11 expression. Finally, large sized SIOH particles affect membrane integrity and viability of cells. All these evidence, suggest a proinflammatory role of silica particles since these molecules, employed in the proper concentrations, and could be used as an adjuvant for immune response against microbial antigens. On the contrary, results with NPs (10 nm) suggest that these NPs could be more biocompatible and less proinflammatory with the potential to be used as delivery of molecules for several purposes unlike immune stimulation or with the correct modifications be used in autoimmune or allergies diseases treatment [106]. In conclusion, SiNPs inhibited proliferation and induced monocyte/macrophages activation but amine grafted silica NPs did not alter these parameters so activation properties of SiNPs could be hindered after grafting with amine moieties [107].

2.3.2.6. Iron nanoparticles. Recent in vitro studies demonstrated the absence of toxicity of iron oxide NPs. Moreover, they do not induce inflammatory responses on human monocyte-macrophages and human aortic endothelia cells but may induce oxidative stress [108,109]. However, in vivo studies showed complex results. For example, Ban et al., (2012) described anti-inflammatory effects after iron oxide NPs instillations and that intratracheally administration inhibited Th2 lymphocytes (related to allergic process) [110]. Lower doses of 147 nm NPs had no significant effect, while 35 nm NPs induced specific Th2 response to ovalbumin [111]. On the other way, both 35 and 147 nm NPs affect lung function, increasing inflammation but decreasing immune responses against sheep erythrocytes. Shen et al. (2012) demonstrated that iron oxide NPs modified Th balance toward Th2 cells and suppressed hypersensitivity after intravenously administration in mice. But most applications of iron oxide are related to in vivo imaging yet [112]. These characteristics could be related to the fact that their accumulation in macrophages induces transient phenotypic and functional changes [113]. In conclusion, there are evidences for both immunostimulatory and immunosuppressive effects of iron NPs [114]. Iron oxide NPs can affect Th balance, but also the immune responses of Th17 cells, a subset of T cells related with some inflammatory pathologies. According to Hsiao et al. (2017), iron oxide NPs decrease infiltration of CCR6+, IL-6+, IL17+ and ROR-γ+ cells in inflamed footpads of ovalbumin (OVA)-sensitized mice and they cause a direct suppressive effect on the expression of IL-6, IL-17 and ROR-γ by OVA-primed splenocytes in culture. All this data indicates that iron oxide NPs attenuate Th17 cell responses in vitro and in vivo [115].

2.3.3. Engineered nanoparticles

With the aim to obtain tools for immunotherapy, researchers work in the construction of complex NPs with different molecules [116–119]. Table 2 presents a summary of complex NPs assayed for autoimmune and allergies diseases treatment. Indeed, different NPs carrying molecules have been tested in diverse biological models. For example, nanomaterials were developed from peptide amphiphiles that respond to the increased levels of matrix metalloproteinases or reactive oxygen species for immunotherapeutic delivery [120]. Engineered nanomaterials have progressed from being a proof of concept to improve traditional applications, including cargo delivery, immune modulation, therapy and imaging [121–123].

2.3.3.1. Oligonucleotide-bearing nanoparticles. Antisense oligonucleotides included in PEG/PVP particles have been used to convert DCs into a suppressive phenotype in a mice model [124]. In the same way, Leuschner et al. succeeded in silencing the expression of CCR2 (chemokine receptor) in order to decrease the recruitment of monocytes and therefore the activation of the innate immune response, using small interfering ribonucleic acids (siRNA) transported by small lipid NPs [125]. Other authors reported NPs of an iron oxide core coated with dextran and conjugated to siRNA to downregulate the expression of major histocompatibility complex (MHC) class I molecules [126]. Ramelli et al. described oligonucleotides complexed with pegylated cationic lipid NPs that reduced obstructive airway remodeling and reduced CD68 immunoreactivity preventing airway inflammation in a model of asthma [127]. In this sense, different NPs that transport anti-inflammatory oligonucleotides are under study [128].

2.3.3.2. Immunosuppressant drugs bearing nanoparticles. Polymer NPs with rapamycin, an immunosuppressant, was developed with the aim to limit its exposure to the kidneys, when was administered via the tail vein into NOD mice. This complex decreased lymphocytic infiltration and represented a low release system that reduces its toxicity in a Sjögren's syndrome model. These preparations worked better than the drug alone [129]. Liposomes loaded with nintedanib and colchicine provided an alternative strategy to module M1/M2 macrophages into a balanced status and consequently module the innate immune response [130]. These type of NPs have interesting features and been also postulated for their application in transplantation medicine [131].

2.3.3.3. Nanoparticles as antigens carriers for immune response control. Other studies use NPs specific to autoantigens. Iron NPs coated with MHC class I or II presenting specific peptides implicated in autoimmune disease induce the expansion of antigen specific regulatory cells, which suppressed autoantigen presentation and restore normoglycemia in different mice models including a humanized one without compromising systemic immunity [132]. This construction showed efficacy in EAE model, collagen-induced arthritis (CIA) and Type 1 Diabetes (T1D) [132–134]. T cell epitope transported by gold particles-polyethylene glycol (PEG) complex NPs are taken by DCs and expanded Foxp3+ Tregs in vitro reducing the severity in EAE and T1D in NOD mice [135,136]. Another study, reported that in order to induce tolerance, authors employed poly(lactide-co-glycolide) NPs with autoantigens and rapamycin (PLG) [137]. These NPs inhibit CD8+ and CD4+ T cells activation and increase regulatory cells in EAE and hemophilia A mice.
Table 2

| Nanoparticle | Cells implicated in immune response/ tissue affected | Molecules regulated | References |
|--------------|-----------------------------------------------------|---------------------|------------|
| Antisense oligonucleotides included in PEG/PVP | Convert DCs into a suppressive phenotype | [124] |
| Small interfering ribonucleic acids (siRNA) transported by small lipid NPs | Decrease the recruitment of monocytes | Silencing the expression of CCR2. | [125] |
| Iron oxide core coated with dextran and conjugated to siRNA | Antigen presenting cells | Down regulate the expression of MHC class I molecules. | [126] |
| Oligonucleotides complexed with pegylated cationic lipid NPs | Reduction of obstructive airway remodeling and CD68 immunoreactivity | Preventing airway inflammation in a model of asthma | [127] |
| Polymer NPs with rapamycin | Decreased lymphocytic infiltration in a Sjögren’s syndrome model. | [129] |
| Iron NPs coated with MHC class I or II presenting specific peptides | Induce the expansion of antigen specific regulatory cells | [132-134] |
| T cell epitope transported by gold particles-polyethylene glycol (PEG) complex NPs | Phagocytosed by DCs. Expanded Foxp3+ Tregs. | [135,136] |
| Poly(lactide-co-glycolide) NPs with autoantigens and rapamycin(PLG). | Inhibit CD8+ and CD4+ T cells activation and increase regulatory cells. | [137,138] |
| Liposomal NPs with inhibitory ligands and antigens | Induce B cell tolerance | Induce inhibitory antibodies | [139] |
| PLG NPs coating with red blood cell membranes | Use as target for pathological antibodies | [140] |
| PLG NPs with antigens | Inhibit of Th2 response. | [141,143] |
| Melanin antigen coupled to PLG NPs | Reduced the presence of Th1 and Th17 lymphocytes and macrophages in the central nervous system | [142] |
| Self-antigen in QDs | Immunological tolerance | [40] |
| Antigen-decorated PLA NPs particles | Inactivate pathogenic T cells and activated Tregs cells. Uptake by macrophages | [144] |
| PLGA NPs delivering OVA and decorated with ligands for scavenger and mannose receptors. | Induce the presence of Foxp3+ Tregs in the lung. | Induction of TGF-β, IL-4, and IL-10 production in vitro. | [51] |
| Fucan-coated Silver NPs | Macrophages | Increase of IL-10, IL-6, TNF-α and nitric oxide. | [180] |

2.3.3.4. Nanoparticles for pH and oxidative stress control. Many inflammatory diseases involve oxidative stress and reduced pH. Pu et al. (2014) described a NP system that is reactive to both reduction of pH and oxidative stress, commonly present in an inflammatory environment. These NPs effectively release curcumin, which is a potent antioxidant and anti-inflammatory agent, and reduce the excess oxidants produced by the lipopolysaccharide (LPS)-stimulated macrophages. This system allows monitoring the intracellular release behavior because of the presence of Förster resonance energy transfer between the carrier and curcumin. Curcumin-loaded NPs applications were also validated in a mouse model with ankle inflammation induced by LPS. This system is a promising tool for treating oxidative stress-related diseases [145]. Moreover, the dual-responsive NPs possess interesting extracellular/intracellular anti-inflammatory mechanisms (Fig. 5).

3. Applications of nanoparticles as adjuvants for vaccine formulation

3.1. Vaccines adjuvants

Many of the current modern vaccines contain purified or recombinant antigens in suspension with excipients, possible components from the production process (egg proteins, formaldehyde, antibiotics, etc.) and adjuvants. Adjuvants are used to enhance the immune response against vaccine antigens.

For many years, only aluminum salts were approved as adjuvants for human use for the FDA of the United States. These aluminum salts-based adjuvants directly activate DCs and can induce strong antibody responses. The mechanism of action involves the adsorption of the desired antigens on the surface of aluminum compounds. This phenomenon can contribute to retain the antigens at a higher concentration in the injection site, therefore providing a sufficient uptake time for DCs [146,147]. Even though, these adjuvants cannot be applied with all antigens, because in some cases can induce local reactions in the injection site and sometimes fail to generateCD8+ T-cell immunity [148]. Currently, there are other adjuvants approved by FDA like MF59, an oil-in-water emulsion of squalene oil used in Flaud, a vaccine for the prevention of seasonal influenza in adults older than 65 years. Another example is CpG 1018, an adjuvant based on synthetic DNA sequences used for Heplisav-B, a vaccine for the prevention of hepatitis B virus infections in 18 years old adults and older.

Actually, it is well-known that APCs, such as DCs, plays a fundamental role in determining the direction of the adaptive immune response. They are the link between the innate and adaptive responses. Therefore, it was suggested that the ideal vaccine, would initiate an innate immune response competent to direct the adaptive immune response in animals with Th2 sensitization [141]. Myelin antigen coupled to PLG NPs reduced the presence of Th1 and Th17 lymphocytes and macrophages in the central nervous system, inducing tolerance in EAE model [142]. Other authors described tolerogenic NPs composted of PLG NPs with antigens that eliminate completely the disease in an EAE mice model [143]. In other work that use a mouse model of multiple sclerosis (MS), Hess et al. showed that by controlling the density of self-antigen in QDs, immunological tolerance can be generated [40]. In addition, intravenous administration of antigen-decorated 500 nm polystyrene or PLA particles inactivated pathogenic T cells and, on the contrary, activated Tregs cells after being uptake by macrophages of the marginal zone. This effect caused T-cell tolerance and ameliorated EAE [144]. More recently, PLGA NPs that deliver OVA and decorated with ligands for scavenger and mannose receptors was developed. These NPs induced TGF-β, IL-4, and IL-10 production in vitro. In vivo experiments demonstrated that NPs suppress anti-OVA IgE responses, Th2 cytokine production, airway eosinophilia and induce the presence of Foxp3+ Tregs in the lung [51].
response toward a specific pathogen, followed by the development of immune memory. If the vaccines fail in inducing APCs maturation, protective immunity is limited [149].

The employment of adjuvants during vaccine formulation ensures the generation of a soft local inflammatory reaction which can efficiently stimulate the recruitment of immune cells and induce the adaptive immunity rapidly. This effect is of particular interest for the induction of protective specific adaptive immunity to vaccine antigens. Most of the particulate adjuvants apparently contribute to the activation of the inflammasome, which is an intracytoplasmic protein complex with the role of detecting stress signals and activating enzymes involved in the production of inflammatory cytokines. Especially, the activation of the inflammasome induces the production of IL-1β. This is an inflammatory cytokine with an important immunostimulatory role [150]. Understanding the mechanisms of interactions of nanomaterials with the inflammasome will provide strategies for safer nanomaterial design and therapy [151].

3.2. Nanoparticles in vaccine formulations

Until now, a great progress has been achieved in the development of conventional vaccines. However, in some cases they require further improvements to completely afford concerns about: i) intrinsic instability in vivo, ii) toxicity, iii) weak immunogenicity, and iv) requirement of multiple administrations. Nanotechnology has emerged as a true candidate to overcome these problems and improve vaccine development. Indeed, nanoparticulate delivery systems provide the possibility to improve both, the humoral and cellular immune responses. The nanoscale size possesses various interesting advantages for vaccine developments among which the facile uptake by phagocytic cells, the mucosa-associated lymphoid tissue and the gut-associated lymphoid tissue, would lead to improvements in antigen recognition and presentation. Moreover, surface modifications of the nanocarriers with different targeting moieties allow the stimulation of selective and specific immune responses through the delivery of antigens to specific receptors present in cell surfaces. In addition, some nanocarriers have been designed to co-deliver both an antigen and an adjuvant. Indeed, nanocarriers can facilitate the targeting and/or sustained release of antigens or adjuvants to APCs [152]. Nowadays, it is clear that nanovaccines represent a key milestone in the prevention of classical and emerging diseases [153].

The employment of NPs with biomedical purposes has brought new concerns that must be addressed. One of these points involves the analysis of the time that they persist in the organism and produce their effects before being recognized and eliminated by the defensive systems. Another important point requires the analysis of the NPs modulation of the immune responses in order to obtain optimal effects. These analyses are highly important for the safety use of NPs in vaccine formulations since NPs can accomplish a dual function. In one hand, NPs can work as delivery system of antigens to enhance antigen processing. On the other hand, NPs can also work as an immunostimulatory adjuvants inducing and amplifying protective immunity. In addition, the degradation rate of the NPs within the cells is another factor that must be considered. NPs must persist enough time to allow efficient antigen uptake, processing, and presentation, although NPs can induce chronic inflammasome activation and pathological unresolved inflammation if they persist too much time. However, NPs can be very good adjuvants because of their physicochemical properties (e.g., shape, size, surface charge), biocompatibility and the possibility to be tailored to attain different immunological effects [150,154].
An important topic to consider before developing NPs vaccines is that after parenteral administration, host proteins are immediately adsorbed on NPs surface, thus immune cells encountering vaccine adjuvant particles do not interact with a clean surface. Instead, such particles incorporate a complex mixture of surface-adsorbed protein immediately after immunization. However, the importance of ‘protein corona’ consequence on vaccine formulations is still underappreciated. While great effort are being performed to clarify the relevance of such interactions, it is clear that if composition and reproducibility of production are not well controlled, it could not be possible to reliably characterize the interactions with the biological environment and the resulting immune responses [155,156].

3.3. Nanoparticles being studied for the development of vaccines

There are different types of NPs such as hard material NPs (i.e.: silica, iron oxide, gold, silver) and organic-based NPs (i.e.: polymeric, lipidic), among others. Depending on the material of the NPs, structure and chemical modifications on the surface, the effects over immune system could change (Table 3). Indeed, various material properties are being exploited to develop effective vaccines [157].

3.3.1. Carbon based particles

3.3.1.1. Carbon nanoparticles. Carbon NPs are also studied for vaccine and drug delivery. They present good biocompatibility and can be synthesized into a variety of mesoporous spheres and nanotubes. Mesoporous carbon NPs have been studied as an oral vaccine adjuvant [158]. Sometimes, a molecule has adjuvant activity but is unstable in physiological conditions, and the binding to a nanoplanform can offer an increase of stability and efficiency. Li et al. (2018) prepared stable NPs by supramolecular assembling of carbon dots (CDs) and Ricin toxin binding subunit B (RTB). However, RTB can modulate cell-mediated immunity and promote the activation of macrophages; its biomedical applications are significantly limited because of the intrinsic properties of proteins, like low efficacy of cellular uptake and poor stability. The formed CDs-RTB possessed robust stability and protected RTB against enzymatic hydrolysis. More importantly, CDs-RTB promoted macrophages proliferation, enhanced the generation of TNF-α, IL-6 and NO in RAW 264.7 cells and increased the expression of mRNA, suggesting the improved immunomodulatory activity of CDs-RTB [159]. Similarly, a nanocomplex formed by multiwalled carbon nanotubes (MWCNTs) and a noncovalent attached synthetic peptide was able to generate a stronger immune response compared to the antigen vaccine without the MWCNTs [160].

3.3.1.2. Liposomes and emulsions. One of the nanosystems of great interest for the scientific community is the liposomes that are biocompatible NPs composed of phospholipid bilayers [161]. They are capable of deliver both hydrophilic and hydrophobic molecules, properties that facilitate the co-delivery of different molecules, such as antigens and adjuvants. The physicochemical properties of liposomes, including their lipid composition, structure and size can be tuned according to the properties of the vaccine antigen to maximize immunogenicity. These properties are also significant for the induction of the immune response. Liposomes composed of dimethyldioctadecyl ammonium (DDA) can affect only the cell-mediated immune response, but not the humoral ones, in a size depending way [162].

In parallel, adjuvant formulations with emulsions have been long studied as vaccine delivery systems. Emulsions are dispersions of two or more immiscible liquids composed of oil, emulsifiers, and excipients. Emulsions can be classified in two main classes: oil-in-water emulsions and water-in-oil emulsions. The first emulsion type is usually used in adjuvant formulations [152]. Emulsions can carry antigens inside their core for efficient vaccine delivery or can also be simply mixed with the antigen. One frequently employed emulsion is MF59, which has been licensed as a potent and safe vaccine adjuvant in more than 20 countries. Indeed, it has been extensively studied for therapeutic application in influenza vaccines. A frequently used adjuvant delivery system in DNA vaccine studies involves a combination of 1,2-dioleoyl-3-trimethylam

| Table 3 |
| Summary of NPs being studied for the development of vaccines. |
| Nanoparticle | Cells implicated in immune response/tissue affected | Molecules regulated | References |
| --- | --- | --- | --- |
| Liposomes composed by DDA, Subcutaneous injection. | Induce the cell-mediated immune response. | Production of IFN-γ and IL-17 in some variants with mycobacterial lipid monomycyol glycerol | [162] |
| Chitosan NPs coated with the Salmomrella surface F protein. | Induction of lymphocyte proliferation. | Increased expression of TLR-4, TLR-2, TGF-β, IL-4, and IFN-γ mRNAs. | [165] |
| Gold nanoparticles, Intranasal administration. | Monocytes, macrophages, T cells, NK cells and DCs. | Decrease of TNF-α, GM-CSF, IL-17 and IL-12p70 and increase of IL-9 in comparison with respiratory syncytial virus infected animals | [166] |
| Hydrophobic Zwitterionic Functionalized Gold NPs in presence of LPS | Macrophages. Pro inflammatory profile. | Increase TNF-α, IL-10. | [167] |
| Hydrophobic Zwitterionic Functionalized Gold NPs in presence of LPS | Macrophages. | Inhibition of oxidative burst, the release of NETs, ROS and histamine. | |
| Carbon Dots and Ricin toxin binding subunit B. Oral vaccine adjuvant. | Promotion of macrophages proliferation | Suppressed expression of TNF-α, Increase of TNF-α, IL-6 and NO. | [159] |
| Silica-based NPs coated with nevirapine (NVP) | Peripheral blood mononuclear cells. NVP coated NPs showed less cytotoxicity than free NVP. | Induce secretion of specific antibodies and IFN-γ | [179] |
| Pulullan-coated iron oxide NPs conjugated with an antigen from Plasmodium yoelii. | CD4+ T cells reactive to this antigen in a rodent malaria challenge model. | Decrease of oxidants (ROS/RNS) produced by the LPS-stimulated Macrophages | [145] |
| Polymeric NPs releasing curcumin | Macrophages | | |

3.3.1.3. Polysaccharide polymeric nanoparticles. Nanosized adjuvants
were also prepared employing natural polymers like polysaccharides (i.e.: chitosan, alginate, inulin, pullulan). Among this group, chitosan-based NPs have been extensively studied due to their biodegradability, biocompatibility, and possibility to be processed into desired sizes and shapes. Indeed, chitosan NPs have been employed in the formulation of different vaccines including Newcastle disease vaccines, HBV vaccines and DNA vaccines. Another potent adjuvant and well-known activator of complement via the alternative pathway is Inulin. Inulin derived NPs were employed as adjuvants. In this sense, AdvaxTM, generated a higher immune response in vaccines against different viruses including respiratory syncytial virus [164]. Other work studied chitosan NPs coated with the Salmonella surface F-protein in chickens. These NPs induced higher levels of specific mucosal IgA production and lymphocyte proliferation as well as increased the expression of TLR-4, TLR-2, TGF-β, IL-4, and IFN-γ mRNA. Chitosan NPs induced antigen-specific T and B cell responses against Salmonella, a common poultry pathogen [165]. A minimal association between antigen and NPs is needed for the formulation of immune potentiator adjuvant. Thus, in most cases the simple mix of NPs and adjuvant shortly prior to injection should be enough to prepare the NPs with a target antigen. This hypothesis was investigated with hard-material NPs adjuvants. It was observed that even when not conjugated to the antigen, NPs can work as a size-dependent immune potentiator adjuvant [158]. Different works further confirms the induction of inflammatory immune responses after injection of hard material NPs without antigen [158].

3.3.2. Non-carbon-based nanoparticles

3.3.2.1. Gold nanoparticles. Gold NPs are platforms extensively studied and with many applications in biomedicine thanks to their binding capacity to multiple molecules as proteins, antibodies and oligonucleotides. The binding between these molecules and gold NPs can modify their physicochemical properties as surface plasmon resonance, conductivity, and redox behavior, giving a possibility to detect signals. Gold nanorods with antigens conjugated on their surfaces were employed in the development of carrier for an antigen derived from respiratory syncytial virus [166]. Different types of gold NPs were used as carriers for various virus derived antigens such as classical swine fever, foot-and-mouth disease and influenza, or as a DNA vaccine adjuvant for human immunodeficiency virus (HIV) [158,167]. Moyano et al. (2016) reported the use of 2-nm-core gold NPs functionalized with zwitterionic and non-ionic tetraethylene glycol ligands. These particles were engineered based on the NPs surface chemistry and biological activities relationship analysis. In this way, it was shown that NPs bearing hydrophobic zwitterionic improve inflammatory response more than hydrophilic zwitterionic ones. However, tetra (ethylene glycol) head groups produce an important anti-inflammatory response (in vitro and in vivo) indicating that the surface ligands after immunomodulatory NPs properties [168].

3.3.2.2. Silica-based nanoparticles. Silica emerged as a candidate to develop delivery systems and the interest for its application in nanovaccinology design is growing fast. SiNPs are generally recognized as safe and possess important physicochemical properties as nanocarriers for different applications, such as real-time multimodal imaging, selective tumor targeting and vaccine delivery. Indeed, these NPs conjugated in a vaccine with inactivated transmissible gastroenteritis virus simultaneously deliver various cargo molecules with different molecular weights and the ability to functionalize their surface highlights silica-based NPs as a promising platform for various applications [107,170–172]. Indeed, silica NPs provide the possibility to improve both, the cellular and humoral immune responses [148]. MSNs with sizes in the range of 50–200 nm have been studied as both nanocarriers and adjuvants for delivery of effective antigens, such as those derived from porcine circovirus and HIV [173,174]. Biocompatibility and internalization of MSNs in macrophage like THP-1 cells is dependent of the particle size, despite their cargo, as it has been shown by Huang et al. (2020). Their results indicated that adjuvant potential of SiNPs can vary depending of their size [175].

The potential of mesoporous silica particles as a vaccine adjuvant was early identified by Mercuri et al., employing SBA-15 as a transport and adjuvant for bacterial recombinant protein Int1b [176]. The authors reported an increased immune response in mice. Moreover, SBA-15 presented better adjuvant properties than Al(OH)3. Although, there was no evidence of in vitro release of the protein from carriers. Mice treated with SBA-15 containing Int1b presented higher antibody titers compared to the mice immunized with protein plus Al(OH)3 adjuvant [148], SBA-16 was also reported as adjuvant system. Recently, through the incorporation of a specific antigen of pathogenic fungus Para-coccidioides brasilienis at silanized SBA-16 (APTES-SBA-16), it has been created a nanosystem with a sustained release profile without significant cytotoxicity on normal human lineage cells [177].

3.3.2.3. Iron oxide nanoparticles. Selective drug transport and its controlled release at the target site can be achieved with aminosilane-coated iron oxide magnetic NPs. DNA vaccines developed with Fe3O4-Glu-polyethyleneimine NPs induced a strong immune response and generate a statistically significant increase in the protective efficacy against infections [178]. Pulullan-coated iron oxide NPs are non-toxic. They were conjugated with an antigen from Plasmodium yoelii to induce both, specific antibodies and IFN-γ CD4+ T cells reactive to this antigen in a rodent malaria challenge model [179].

3.3.2.4. Silver nanoparticles coated with biomolecules. Fernandes-Negreiros et al. (2017), synthesized silver NPs containing fucans from Dictyotamertensii (Martius) Kutzing using an environmentally friendly method. Fucan-coated silver NPs (FN) were size-stable for 16 months. They inhibited melanoma tumor cell line B16F10 proliferation. Additionally, they increased the release of cytokines (IL-10; IL-6 and TNF-α) and nitric oxide up to 7000 times. In addition, the FN showed Gram-positive and -negative bacteria inhibitory effects [180]. Sharma et al. synthesized curcumin-stabilized silver 45 nm NPs (Cur-AgNP). They observed a significantly reduced HIV 1 replication in cells treated with Cur-AgNP by inhibition of proinflammatory cytokines (IL-6, TNF-α, and IL-1β) and translocation of nuclear NF-kB [181]. Although, the interaction of silver NPs with immune system is not really understood. Orłowski et al. (2018), studied the ability of tannic acid-modified silver NPs to induce DCs maturation and activation. Both types of NPs were efficiently internalized by DCs and induced maturation and TLR9 expression. Moreover, the uptake of NPs was blocked by an inhibitor of clathrin-mediated endocytosis of NPs and there was a low co-localization of NPs with lysosomes (Fig. 6) [182].

4. Nanoparticles targeting

Disease nanoparticles have significantly changed with the development of NPs with the ability to accurately target desired cells or organs (Table 4). For example, TLR receptors can be efficiently targeted employing NPs grafted with surface TLR ligands which can bind and activate them. The adjuvant AS04 is a precursor of this concept made ofTLR4 ligands (MPL) on alum particles. Moreover, NPs can be engineered or modified in order to improve the rupture of the phagolysosome after
Fig. 6. Intracellular localization of TA-Ag/AuNPs. The Manders’ coefficients for co-localization of TA-Ag/AuNPs and cytoplasm (A) or lysosomes (B) in JAWS II cell culture exposed to 10 nm, 37 nm, 59 nm TA-AgNPs and 10 nm, 34 nm, 62 nm TA-AuNPs for 24 h at 2.5 μg/ml. *Significant differences with \( p \leq 0.05 \). (C) Representative images for lysosomes (green), NPs (red) and nuclei (blue) in cells exposed to NPs, as described above. (D) NPs content in cells subjected to pre-treatment with 10 μg/ml monodansylcéduerine and 5 μg/ml cytochalasin D, and then to incubation with TA-Ag/AuNPs at 2.5 μg/ml for 6 h. Reprinted from [182] with permission from Frontiers under the terms of the Creative Commons Attribution License (CC BY).
being incorporated by APCs. Examples of these engineered NPs include the crystalline particles (e.g., alum) and membrane-active particles (e.g., the protons sponge particles). As a consequence of the phagosomesosomal rupture, antigens and inflammasome-activating molecules escape to the cytoplasm and this process enhance cross-presentation. For that, to act as great adjuvants NPs must provide to the cells all the stimuli required, including the ability to upregulate IL-1β gene and activate inflammasome [183–185]. However, IL-1β and inflammasomes are also involved in a great variety of diseases, including degenerative diseases, acute and chronic inflammatory diseases, cancer, autoimmune diseases, among others. So, the balance between local beneficial (protective) inflammation and pathological inflammation is diffuse, and is principally based on the duration and persistence of the stimulus [150].

4.1. Carbon based particles

4.1.1. Lipid nanoparticles

Swaminathan et al. (2015) analyzed a novel Merck proprietary lipid NP (LNP) in order to improve immune stimulation against viral antigens. BALB/c and C57BL/6 mice models immunized with LNPs alone or in combination with TLR9 agonist, immunomodulatory oligonucleotides, IMO-2125 (IMO), presented significantly enhanced immune responses to hepatitis B virus surface antigen (HBsAg) and ovalbumin (OVA). B-cell responses to both antigens tested were enhanced by LNPs, to levels comparable to known adjuvants including aluminum-based adjuvant, a TLR4 agonist, 3-O-deacytated monophosphoryl lipid A (MPL), and IMO alone. LNP/IMO agonist combination elicited a stronger Th1-type response. Moreover, antigen specific cell-mediated immune responses were significantly enhanced by the LNP adjuvant. Furthermore, LNPs elicited potent antigen-specific CD8+ and CD4+ T-cell responses. In the same way, LNP and LNP/IMO formulated antigens led to higher frequency of antigen-specific CD8+ T-cell responses, than antigens alone or vaccine with only IMO. These results show that lipid NPs can be useful as future vaccine adjuvant to in vivo improve both T-cell and B-cell responses [186]. On the other hand, targeted NPs could be useful for cancer treatment. In this sense, it was reported an engineered tumor-targeted lipid-dendrimer-calcium-phosphate (TT-LDPC) NPs with thymine-functionalized dendrimers, that enhanced gene delivery capacity with adjuvant properties. TT-LDPC NPs delivered siRNA against ligand PD-L1 and IL-2 achieving tumoral infiltration and activation of CD8+ T cells [187].

4.1.2. Lipid-polymer hybrid NPs (LPNPs)

Asthana et al. (2015) developed macrophage targeted cationic stearylamine lipid–polymer hybrid NPs (LPNPs) with liposomes and polymeric NPs. LPNPs were adapted for the delivery of Amphotericin B (AmpB) in order to enhance therapeutic efficacy and diminishing toxic effect. LPNPs core-shell structure has the ability to encapsulate amphiphilic AmpB in higher amount in a stabilized formulation and sustain drug release. LPNPs demonstrated safe applicability for parenteral administration, high macrophage incorporation and great anti-leishmanial efficacy in vitro and in vivo due to Th-1 biased immune-alteration mediated by drug-free LPNPs which increased macrophages microbicidal mediators. AmpB-LPNPs could be a promising alternative to commercial AmpB-formulations for the eradication of intramacrophage diseases [188]. Other authors developed a hyaluronic acid (HA) decorated, pH sensitive LPNPs to deliver two compounds: erlotinib and bevacizumab for targeting and suppressing non-small cell lung cancer. NPs reduced the tumor volume respect control group, so it was postulated as a promising system for the therapy of this type of cancer [189].

4.1.3. Oligonucleotides to target APCs

Efficient delivery of antigens is of great concern in immunotherapies. Molino et al., (2017) conjugated E2 protein NPs (CpG-PEG-E2) with CpG oligonucleotides to target APCs. CpG-PEG-E2 was uptake by APCs in vitro and in vivo, and showed enhanced lymph node retention up to at least 48 h. Both parameters are helpful for vaccine success. This suggests that enhanced APC uptake of NPs mediated by oligonucleotide display may help vaccine development overcoming delivery barriers [190].

4.2. Non-carbon-based nanoparticles

4.2.1. Porous silica NPs

DCs are the most potent APCs and are fundamental for transplant tolerance. A possible target for DCs therapy is the DCs specific intra-cellular adhesion molecule-3-Grabbing Non-integrin (DC-SIGN; CD209) receptor. In this way, biodegradable porous silicon (pSi) NPs with high-surface area displaying antibodies anti-DC-SIGN and loaded with the immunosuppressant rapamycin (Sirolimus) was developed to target DCs. These NPs not only target but were phagocytosed by monocyte-derived and myeloid DCs in a time- and dose-dependent manner (Fig. 7). Rapamycin-loaded NPs, resulted in a maturation resistant receptor. In this way, biodegradable porous silicon (pSi) NPs with high-surface area displaying antibodies anti-DC-SIGN and loaded with the immunosuppressant rapamycin (Sirolimus) was developed to target DCs. These NPs not only target but were phagocytosed by monocyte-derived and myeloid DCs in a time- and dose-dependent manner (Fig. 7). Rapamycin-loaded NPs, resulted in a maturation resistant receptor. In this way, biodegradable porous silicon (pSi) NPs with high-surface area displaying antibodies anti-DC-SIGN and loaded with the immunosuppressant rapamycin (Sirolimus) was developed to target DCs. These NPs not only target but were phagocytosed by monocyte-derived and myeloid DCs in a time- and dose-dependent manner (Fig. 7). Rapamycin-loaded NPs, resulted in a maturation resistant receptor. In this way, biodegradable porous silicon (pSi) NPs with high-surface area displaying antibodies anti-DC-SIGN and loaded with the immunosuppressant rapamycin (Sirolimus) was developed to target DCs. These NPs not only target but were phagocytosed by monocyte-derived and myeloid DCs in a time- and dose-dependent manner (Fig. 7). Rapamycin-loaded NPs, resulted in a maturation resistant receptor. In this way, biodegradable porous silicon (pSi) NPs with high-surface area displaying antibodies anti-DC-SIGN and loaded with the immunosuppressant rapamycin (Sirolimus) was developed to target DCs. These NPs not only target but were phagocytosed by monocyte-derived and myeloid DCs in a time- and dose-dependent manner (Fig. 7). Rapamycin-loaded NPs, resulted in a maturation resistant receptor. In this way, biodegradable porous silicon (pSi) NPs with high-surface area displaying antibodies anti-DC-SIGN and loaded with the immunosuppressant rapamycin (Sirolimus) was developed to target DCs. These NPs not only target but were phagocytosed by monocyte-derived and myeloid DCs in a time- and dose-dependent manner (Fig. 7). Rapamycin-loaded NPs, resulted in a maturation resistant receptor. In this way, biodegradable porous silicon (pSi) NPs with high-surface area displaying antibodies anti-DC-SIGN and loaded with the immunosuppressant rapamycin (Sirolimus) was developed to target DCs. These NPs not only target but were phagocytosed by monocyte-derived and myeloid DCs in a time- and dose-dependent manner (Fig. 7). Rapamycin-loaded NPs, resulted in a maturation resistant receptor. In this way, biodegradable porous silicon (pSi) NPs with high-surface area displaying antibodies anti-DC-SIGN and loaded with the immunosuppressant rapamycin (Sirolimus) was developed to target DCs. These NPs not only target but were phagocytosed by monocyte-derived and myeloid DCs in a time- and dose-dependent manner (Fig. 7). Rapamycin-loaded NPs, resulted in a maturation resistant receptor. In this way, biodegradable porous silicon (pSi) NPs with high-surface area displaying antibodies anti-DC-SIGN and loaded with the immunosuppressant rapamycin (Sirolimus) was developed to target DCs. These NPs not only target but were phagocytosed by monocyte-derived and myeloid DCs in a time- and dose-dependent manner (Fig. 7). Rapamycin-loaded NPs, resulted in a maturation resistant
4.3. Engineered nanoconstructions

Some nanoconstructions have a complex structure. Polyion complex vesicles (PICosomes) are polymeric hollow capsules. They are versatile platform for drug-loaded nano-formulation composed by a semipermeable membrane. Goto et al. (2017), successfully encapsulated MSNs into the PICosomes (MSN@PICsome). MSN@PICsome was stably under physiological condition and mice blood circulation. Furthermore, the surface of MSN in MSN@PICsome can be modified, obtaining amino-functionalized and sulfonate-functionalized MSN@PICosomes (A-MSN@PICsome and S-MSN@PICsome, respectively). Both surface-modified MSN@PICosomes were successfully loaded with charged water-soluble low-molecular-weight compounds (LMWCs). Particularly, S-MSN@PICsome with gemcitabine (GEM) released it in a continued manner. GEM-loaded S-MSN@PICsome demonstrated marked cytotoxicity against cultured tumor cells, and suppressed the growth of lung tumor in in vivo model [193]. Furthermore, Battistella et al., (2019), reported that covalently packaging low molecular weight immunotherapeutics in enzyme-responsive NPs maintains drug efficacy while decreasing immunotoxicity. Indeed, after parent administration of the immunotherapeutic small molecule (1V209), mice experience significantly increased plasma levels of proinflammatory cytokines IP-10, IL-6, and MCP-1, while no increase was observed with the nanomaterial, thus, providing an interesting platform for cancer immunotherapeutic delivery [194].

Mueller et al. (2015) developed a vaccine delivery platform based on PRINT hydrogels of biocompatible hydroxy-poly(ethylene glycol) (PEG). This platform was able to activate the alternative pathway of
complement system. These lymph node-targeting NPs showed comparable adjuvant effect to Alum and promoted the immunogenicity of ovalbumin, demonstrating that an antigen-specific humoral response is correlated with antigen delivery to the draining lymph nodes. The easy chemistry used in antigen conjugation to PRINT NPs confers versatility, allowing for potential application to many infectious diseases [108].

5. Some considerations to keep in mind

Until now, it has been described in many reported studies that NPs can produce an immunomodulatory phenomenon. Therefore, analyze which factors are needed to produce immunostimulant or immunosuppression effects represents a key field of research. NPs nature such as composition, size, shape, surface chemistry and protein-binding capability establishes NPs interactions, but it must be taken into account the individual difference and exposure route [195,196]. Systemic administration of NPs favors accumulation in the organs and tissues but it should be noted that the size of particles influences which will be the accumulation site [197]. The immune response is dependent on the route of NPs entrance because different cells and molecules are present in different organs such as epithelium (i.e.: DCs, macrophages) or blood, (i.e.: neutrophil, eosinophil, basophil, lymphocyte, monocyte) with different results in immune stimulation. The reticule endothelial system and the mononuclear phagocyte system clearance can be avoided by NPs < 100 nm, but those < 5.5 nm can be excreted in the urine [198]. NPs-cells interaction is also determined by NPs size. In this way, Shao et al. described that DC preferentially internalize small sized particles, while larger ones are taken up by macrophages [199]. Immunity was induced by series of polystyrene nanobeads with different size. It was observed that IFN-γ induction from CD8+/T-cells was limited to 40 and 49 nm beads. Meanwhile 93–123 nm beads induced CD4+/T-cell activation and increased the levels of IL-4. These results highlight the effect of the NPs size on the cytokine balance. Thus, the size is a key factor to be considered in the development of vaccines against common human pathogens. Same NPs demonstrate that inflammatory activity increase with the size (gold NPs) but others such as iron oxide NPs and CdS/GdTe QD have the inverse behavior [200].

As discussed previously, the composition of NPs has an important participation in the type of interactions established with the immune system. Moreover, in the case of NPs with similar composition, surface properties can change the interaction with the immune system. Indeed, various NPs (i.e.: silica, GNPs, CNTs, fullerences) can be grafted with different moieties on their surface, that modifies the immune response induced [201]. Furthermore, other important factor is the charge of NPs; this can be modified with surface coatings and, in this way, tune their interaction with the immune system. Positive particles would primarily elicit a Th1 cells response and would be more readily captured by DCs [202–204]. On the other way, negative particles are associated with MARCO, a scavenger receptor of macrophages [205]. NPs shape and structure are also determinant for the uptake by cells and immune system interaction [206–208]. Finally, biomolecules NPs interaction are important for corona formation and further effects on cellular uptake and biodistribution. Protein corona formation also depends on NPs size and charge [209,210]. Plasma proteins are able to bind NPs surfaces, contributing to the interaction with receptors and the consequent activation/deactivation of cells [211,212]. Definitively, the interactions of cells with NPs and consequently the biological responses generated are affected by the amount and composition of proteins adsorbed on the NPs surface [213,214]. The induced immune response by NPs could be of great utility in nanomedicine applications such as bone [215] or periodontal tissue regeneration [216]. Increasing the knowledge about immune response and their interaction with NPs is crucial for NPs immunomodulation therapies development.

6. Conclusion

The development of NPs with potential therapeutic uses is an area of vast interest in the scientific community during the last years. Recently, the pandemic caused by COVID-19 motivated a race for the development of vaccines to overcome the crisis generated. In this sense, some of the most advanced developments under study are based on NPs [217–219]. This is a good demonstration that nanotechnology will most likely be the basis of future immunotherapy. Indeed, NPs have been used for a variety of therapeutic applications. A great number of delivery systems based on NPs design have been explored to improve the safety and effectiveness of drugs. The fundamental advantages of NPs are: i) targeted delivery to the immune system, ii) improved delivery of water-insoluble drugs, iii) co-delivery of two or more drugs for combined therapy, iv) gene silencing by gene therapy, and v) theragnostic uses. In the last years, the number of publications based on these systems has increased and it is expected that there will be many developments soon that go on to experimentation in clinical stages.

In this review we have described many of the advances that have been developed in order to obtain novel tools for the treatment of allergies, autoimmune diseases and for their use in vaccines. Today many classes of NPs are under study to develop, in the near future, new therapeutic strategies that employ our own immune system in order to direct it to a specific objective, while minimizing the adverse effects present in many of the current treatments.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

E. G. is grateful for his doctoral fellowship granted by CONICET. The authors would like to acknowledge the support of grants from the Universidad de Buenos Aires UBACYT 20020150100056BA and PIDAE 2019 (to M.F.D.), and from Universidad Nacional de Luján CDD-CB-075-16 and 119-18 (to M.C.D.M). Gorka Orive wish to thank the Spanish Ministry of Economy, Industry, and Competitiveness (PID2019-106094RBA-100/AEI/10.13039/501100011033) and technical assistance from the ICTS NANSBIOIS (Drug Formulation Unit, U10) at the University of the Basque Country. We also appreciate the support from the Basque Country Government (Grupos Consolidados, No ref: IT907-16). ADP would like to acknowledge the Danish Council for Independent Research (Technology and Production Sciences, 8105–0003B) and the VIDI research programme with project number R004387, which is (partly) financed by the Netherlands Organization for Scientific Research (NWO).

References

[1] R. Medzhitov, C.A. Janeway, Innate immunity; impact on the adaptive immune response, Curr. Opin. Immunol. 9 (1997) 4–9, https://doi.org/10.1016/S0952-7915(97)80152-5.
[2] L.B. Nicholson, The immune system, Essays Biochem. 60 (2016) 275–301, https://doi.org/10.1042/EBC20160017.
[3] M.F. Hajnik, L. Du Pasquier, Evolution of innate and adaptive immunity: can we draw a line? Trends Immunol. 25 (2004) 640–644, https://doi.org/10.1016/j.ti.2004.10.001.
[4] H. Ren, Y. He, J. Liang, Z. Cheng, M. Zhang, Y. Zhu, C. Hong, J. Qin, X. Xu, J. Wang, Role of liposome size, surface charge, and PEIylation on rheumatoid arthritis therapy, ACS Appl. Mater. Interfaces 11 (2019) 20304–20315, https://doi.org/10.1021/acsami.8b02693.
[5] T. Cheng, Y. Zhang, J. Liu, Y. Ding, H. Ou, F. Huang, Y. An, Y. Liu, J. Liu, L. Shi, Ligand-switchable micellar nanocarriers for prolonging circulation time and enhancing targeting efficiency, ACS Appl. Mater. Interfaces 10 (2018) 5296–5304, https://doi.org/10.1021/acsami.7b18137.
[6] Y. Liu, R. Dai, Q. Wei, W. Li, G. Zhu, H. Chi, Z. Guo, L. Wang, C. Cui, J. Xu, K. Ma, Dual-functionalized janus mesoporous silica nanoparticles with active targeting
